MAZE THERAPEUTICS INC (MAZE) Stock News

USA - NASDAQ:MAZE - US5787841007 - Common Stock

30.49 USD

+1.89 (+6.61%)

Last: 11/10/2025, 8:05:03 PM

30.49 USD

0 (0%)

After Hours: 11/10/2025, 8:05:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MAZE Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

5 days ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

5 days ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

5 days ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

2 months ago - By: Investor's Business Daily

Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results

7 days ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

a month ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

a month ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

2 months ago - By: Benzinga

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

2 months ago - By: Benzinga - Mentions: GRI PACS XCUR REVB ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

2 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

2 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

2 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

2 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

2 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

3 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

3 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

4 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

4 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

6 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

6 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

6 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

6 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

6 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

6 months ago - By: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference